Search clinical trials for: Quetiapine (Seroquel XR® 800 mg/day)

Total 635 results

H. Lundbeck A/S

Completed

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Severance Hospital

Unknown

Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) (ES-ARMS)

Schizophrenia | Abnormal Mental State

Korea, Republic of
University Hospitals Cleveland Medical Center
National Alliance for Research on Schizophrenia and Depression; AstraZeneca

Completed

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

Anxiety Disorders | Anxiety | Bipolar Disorder | Substance Use Disorders

United States
AstraZeneca

Completed

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

Schizophrenia

Malaysia
AstraZeneca

Completed

Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (eXtRa)

Schizophrenia

Italy, Germany, Austria, Spain, Denmark
Inje University

Unknown

The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope

Major Depressive Disorder

Korea, Republic of
BC Women's Hospital & Health Centre

Completed

Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II

Postpartum Depression

Canada
Sunnybrook Health Sciences Centre
AstraZeneca

Completed

Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

Depressive Disorder, Major

Canada
Indiana University School of Medicine
AstraZeneca

Completed

Brain Imaging of Quetiapine Response in Anxious Depression

Major Depression

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
AstraZeneca

Terminated

Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy (RELEASE)

Acute Bipolar Mania

Korea, Republic of
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Indiana University
AstraZeneca

Completed

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

Panic Disorder

United States
University of North Carolina, Chapel Hill
AstraZeneca

Completed

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

Functional Bowel Disorders

United States
AstraZeneca

Completed

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Bipolar Depression
Bayside Health
AstraZeneca

Unknown

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

Schizophrenia | Psychosis

Australia
AstraZeneca

Terminated

Seroquel XR in Adults With Schizophrenia

Schizophrenia

Thailand
Sumitomo Pharma America, Inc.

Completed

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Schizophrenia

United States, Romania, Russian Federation, Ukraine
Emory University
Duke University; University of Toronto

Terminated

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

Cognitive Impairment | Bipolar Disorder

United States
Jazz Pharmaceuticals

Completed

Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

Fatty Liver

United Kingdom
AstraZeneca

Completed

Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) (QUENCH)

Schizophrenia

Korea, Republic of
University Hospital Muenster
AstraZeneca

Completed

Quetiapine in Specific Phobia (QUISS)

Specific Phobia

Germany
Duke University

Terminated

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Social Anxiety Disorder

United States
AstraZeneca

Completed

Pediatric Bipolar Depression

Bipolar Depression

United States, Mexico, Taiwan, South Africa, Serbia, India, Colombia
AstraZeneca

Completed

Generalized Anxiety Disorder Adjunct Study

Anxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety States

United States
AstraZeneca
Quintiles, Inc.

Completed

Adult Bipolar Mania

Acute Mania

Bulgaria, Poland, Russian Federation, South Africa, Germany, Ukraine, Israel, India, Belgium
NanOlogy, LLC
US Biotest, Inc.

Terminated

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Ovarian Carcinoma

United States
Subhajit Chakravorty

Completed

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Alcoholism | Sleep Initiation and Maintenance Disorders

United States
Khon Kaen University
Government Pharmaceutical Organization

Completed

Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

Healthy

Thailand
Icahn School of Medicine at Mount Sinai
AstraZeneca

Completed

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

Generalized Anxiety Disorder | Major Depressive Disorder

United States
AstraZeneca

Completed

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia (SPECTRUM)

Schizophrenia

Canada, Australia, Korea, Republic of, Hong Kong
Astellas Pharma Inc

Completed

Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder

Major Depressive Disorder

Japan
Boehringer Ingelheim

Completed

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

HIV Infections
University of Calgary
AstraZeneca

Completed

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Major Depressive Disorder

Canada
Weill Medical College of Cornell University
AstraZeneca

Terminated

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

Generalized Anxiety Disorder | Major Depression

United States
Hospital de Clinicas de Porto Alegre

Unknown

Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR

BIPOLAR DISORDER

Brazil
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Vedic Lifesciences Pvt. Ltd.

Not yet recruiting

A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

Upper Respiratory Tract Infections

India
Loyola University

Completed

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

Depression | Anxiety

United States
Federal Budgetary Research Institution State Research...

Completed

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
McMaster University

Completed

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Insomnia | Hot Flashes | Major Depressive Disorder

Canada
Keming Gao
AstraZeneca

Terminated

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder (MDD/GAD)

Generalized Anxiety Disorder | Major Depressive Disorder

United States
Université de Sherbrooke
Université de Montréal

Completed

Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study

Fibromyalgia

Canada
University of Saskatchewan
AstraZeneca

Completed

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Depressive Disorder, Major
Joint Stock Company "Farmak"

Completed

Fed Bioequivalence Study of 2 Metformin 500 mg Prolongued Release Tablets in 28 Healthy Male and Female Volunteers

Pharmacokinetics

Czechia
Mayo Clinic

Completed

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

Delirium | Dementia

United States
AstraZeneca

Completed

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

Schizophrenia

China
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy

Bipolar Disorder | Bipolar Depression

Spain
University of Minnesota
AstraZeneca; University of Iowa; Mclean Hospital

Completed

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Borderline Personality Disorder

United States

3

Subscribe